References
- National Health Survey 2010: Epidemiology & Disease Control Division, Ministry of Health, Singapore. Available from: https://www.moh.gov.sg/resources-statistics/reports/national-health-survey-2010.
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:https://doi.org/10.1183/09031936.00202013.
- Tay TR, Wong HS, Ihsan R, Toh HP, Choo X, Tee AK. Comparison of the proportion and healthcare utilisation of adult patients with uncontrolled severe asthma versus non-severe asthma seen in a Southeast Asian hospital-based respiratory specialist clinic. Ann Acad Med Singapore. 2017;46(6):217–228.
- Koh MS, Yii AC, Ong YY. Asthma in Singapore: past, present and future. Ann Acad Med Singap. 2017;46(3):81–83.
- Chai H, Koh M. Zero tolerance towards asthma deaths in Singapore: role of the family doctor. SFP. 2019;44(4):10–13. doi:https://doi.org/10.33591/sfp.44.4.u2.
- Yii ACA, Tay TR, Puah SH, Lim HF, Li A, Lau P, Tan R, Neo LP, Chung KF, Koh MS. Blood eosinophil count correlates with severity of respiratory failure in life-threatening asthma and predicts risk of subsequent exacerbations. Clin Exp Allergy. 2019;49(12):1578–1586. doi:https://doi.org/10.1111/cea.13465.
- Mepolizumab for treating severe refractory eosinophilic asthma, Technology appraisal guidance [TA431]: National Institute for Health and Care Excellence. Available from: https://www.nice.org.uk/guidance/ta431.
- Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:https://doi.org/10.1056/NEJMoa1403291.
- Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, ten Brinke A. Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:https://doi.org/10.1016/s2213-2600(17)30125-x.
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:https://doi.org/10.1056/NEJMoa1403290.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:https://doi.org/10.1016/s0140-6736(12)60988-x.
- McDonald VM, Maltby S, Reddel HK, King GG, Wark PA, Smith L, Upham JW, James AL, Marks GB, Gibson PG. Severe asthma: Current management, targeted therapies and future directions-A roundtable report. Respirology. 2017;22(1):53–60. doi:https://doi.org/10.1111/resp.12957.
- Beasley R. Unmet need in inadequately controlled asthma. Respirology. 2007;12(s3):S18–S21. doi:https://doi.org/10.1111/j.1440-1843.2007.01046.x.
- Pearce F, Lin L, Teo E, Ng K, Khoo D. Health technology assessment and its use in drug policies: Singapore. Value Health Reg Issues. 2019;18:176–183. doi:https://doi.org/10.1016/j.vhri.2018.03.007.
- Drug Evaluation Methods and Process Guide v2.0 Agency for Care Effectiveness, Ministry of Health, Singapore. Available from: https://www.ace-hta.gov.sg [last accessed 12 August 2020].
- Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation: agency for Care Effectiveness, Ministry of Health, Singapore. Available from: https://www.ace-hta.gov.sg/our-guidance/novel-oral-anticoagulants-noacs-for-the-prevention-of-stroke-and-systemic-embolism-in-non-valvular-atrial-fibrillation-rivaroxaban-dabigatran-and-apixaban.html [last accessed 12 August 2020].
- LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD): Agency for Care Effectiveness, Ministry of Health, Singapore. Available from: https://www.ace-hta.gov.sg/our-guidance/lama-_-lama-laba-for-chronic-obstructive-pulmonary-disease.html [last accessed 12 August 2020].
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus: Agency for Care Effectiveness, Ministry of Health, Singapore. Available from: https://www.ace-hta.gov.sg/our-guidance/sodium-glucose-co-transporter-2-sglt2-inhibitors-for-type-2-diabetes-mellitus.html [last accessed 12 August 2020].
- Common Drug Review Pharmoeconomic Review Report For Nucala CADTH. Available from: https://www.cadth.ca/mepolizumab.
- Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S. Mepolizumab for treating severe eosinophilic asthma: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(2):131–144. doi:https://doi.org/10.1007/s40273-017-0571-8.
- Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220–225. doi:https://doi.org/10.1016/j.anai.2016.10.028.
- Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks. Institute for Clinical and Economic Review, December 20, 2018.
- Clinical Review BLA 125526 NUCALA (mepolizumab). U.S Food & Drug Administration; 2015.
- Chew HC, Eng P. Asthma fatalities at the Emergency Department of the Singapore General Hospital. Eur J Emerg Med. 2007;14(1):32–34. doi:https://doi.org/10.1097/01.mej.0000224433.43999.ce.
- M810011 - Singapore Residents By Age Group, Ethnic Group And Sex, End June, Annual: Department of Statistics Singapore. Available from: https://www.tablebuilder.singstat.gov.sg/publicfacing/createDataTable.action?refId=14911.
- Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27. doi:https://doi.org/10.3132/pcrj.2007.00002.
- Sullivan PW, Slejko JF, Sculpher MJ, Ghushchyan V. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804. doi:https://doi.org/10.1177/0272989x11401031.
- Shuyu Ng C, Toh MP, Ko Y, Yu-Chia Lee J. Direct medical cost of type 2 diabetes in singapore. PloS One. 2015;10(3):e0122795. doi:https://doi.org/10.1371/journal.pone.0122795.
- Fee Benchmarks and Bill Amount Information: Ministry of Health Singapore. Available from: https://www.moh.gov.sg/cost-financing/fee-benchmarks-and-bill-amount-information.
- Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:https://doi.org/10.1016/j.jval.2010.09.011.
- Agency for Care Effectiveness: Ministry of Health, Singapore. Available from: https://www.ace-hta.gov.sg [last accessed 12 August 2020].
- Nguyen HV, Bose S, Mital S, Yii ACA, Ang SY, Lam SSW, Anantham D, Finkelstein E, Koh MS. Is bronchial thermoplasty cost-effective as treatment for problematic asthma patients? Singapore's perspective on a global model. Respirology. 2017;22(6):1102–1109. doi:https://doi.org/10.1111/resp.13027.
- Oh HC, Chow WL, Gao Y, Tiah L, Goh SH, Mohan T. Factors associated with inappropriate attendances at the emergency department of a tertiary hospital in Singapore. Singapore Med J. 2020;61(2):75–80. doi:https://doi.org/10.11622/smedj.2019041.
- Ng TP, Lim TK, Abisheganaden J, Eng P, Sin FL. Factors associated with acute health care use in a national adult asthma management program. Ann Allergy Asthma Immunol. 2006;97(6):784–793. doi:https://doi.org/10.1016/s1081-1206(10)60970-2.
- Lim SF, Wah W, Pasupathi Y, Yap S, Koh MS, Tan KL, Chay CJ, Ong ME. Frequent attenders to the ED: patients who present with repeated asthma exacerbations. Am J Emerg Med. 2014;32(8):895–899. doi:https://doi.org/10.1016/j.ajem.2014.04.052.
- Tan NC, Chen Z, Soo WF, Ngoh AS, Tai BC. Effects of a written asthma action plan on caregivers' management of children with asthma: a cross-sectional questionnaire survey. Prim Care Respir J. 2013;22(2):188–194. doi:https://doi.org/10.4104/pcrj.2013.00040.
- Wong AJW, Chan JJ, Koh MS, Lian SWQ, Fook SMC, Ong MEH. Compliance with asthma guidelines and association with outcomes in the Emergency Department of a Tertiary Care Teaching Hospital. J Acute Med. 2018;8(3):119–126.
- Zainudin BMZ, Kai Wei Lai C, Soriano JB, Jia-Horng W, De Guia TS, Asthma Insights and Reality in Asia-Pacific (AIRIAP) Steering Committee. Asthma control in adults in Asia-Pacific. Respirology. 2005;10(5):579–586. doi:https://doi.org/10.1111/j.1440-1843.2005.00753.x.
- Abdulwadud OA, Abramson MJ, Forbes AB, Walters EH . The relationships between patients' related variables in asthma: iplications for asthma management. Respirology. 2001;6(2):105–112. doi:https://doi.org/10.1046/j.1440-1843.2001.00316.x.
- Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18(1):129. doi:https://doi.org/10.1186/s12931-017-0614-x.
- Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, Alacqua M, Tran TN. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–293. doi:https://doi.org/10.1164/rccm.201904-0903SO.
- Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. JMCP. 2016;22(7):833–847. doi:https://doi.org/10.18553/jmcp.2016.22.7.833.
- Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. JAA. 2018;11:193–204. doi:https://doi.org/10.2147/JAA.S176026.
- Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110–116.e7. doi:https://doi.org/10.1016/j.jaci.2017.04.009.
- Sweeney J, Patterson CC, Menzies-Gow A, Niven RM, Mansur AH, Bucknall C, Chaudhuri R, Price D, Brightling CE, Heaney LG. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the British thoracic difficult asthma registry. Thorax. 2016;71(4):339–346. doi:https://doi.org/10.1136/thoraxjnl-2015-207630.
- Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. Epub 2018/09/08. doi:https://doi.org/10.1183/13993003.00703-2018.
- Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J, Kerkhof M, Ow M, Tran TN. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273–283. doi:https://doi.org/10.1111/all.13556.
- Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev. 2020;29(155):190151–190105. doi:https://doi.org/10.1183/16000617.0151-2019.
- Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161–172. doi:https://doi.org/10.1111/resp.13730.
- Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:https://doi.org/10.1183/13993003.02420-2019.
- Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. JAA. 2020;13:77–87. doi:https://doi.org/10.2147/jaa.s236609.
- Taille C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, Charriot J, Bouee S, Gruber A, Pribil C, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020;55(6):1902345. doi:https://doi.org/10.1183/13993003.02345-2019.